Gastric cancer remains a major global health burden, with limited response rates to current immunotherapies targeting the programmed death-ligand 1 (PD-1/PD-L1) axis. Recent studies have identified sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC-15) as a novel immune checkpoint molecule that may drive immune evasion through PD-L1–independent pathways. This study aimed to evaluate the expression patterns of SIGLEC-15 and PD-L1 in gastric adenocarcinoma and to investigate their associations with clinicopathological features and patient outcomes. We retrospectively analyzed 133 consecutive cases of gastric adenocarcinoma with complete clinicopathologic and follow-up data. Immunohistochemical staining was performed on formalin-fixed tumor samples; SIGLEC-15 expression on tumor cells was quantified by H-score (high expression defined as ≥110) and PD-L1 status by combined positive score (CPS, positive if ≥1). High SIGLEC-15 expression correlated with multiple adverse pathological features, including lymphatic (p = 0.003), venous (p = 0.030), and perineural invasion (p = 0.010), and was associated with significantly poorer 3-year overall survival (hazard ratio = 3.36, p < 0.001). While SIGLEC-15 and PD-L1 expression were not mutually exclusive, an inverse relationship was generally observed. Patients with dual positivity (SIGLEC-15 high/PD-L1 CPS ≥ 1) showed the lowest 36-month survival (32%), compared to 56% in the dual-negative group (SIGLEC-15 low/PD-L1 CPS < 1). These results highlight the clinical relevance of SIGLEC-15 as an independent marker of tumor aggressiveness and poor prognosis in gastric adenocarcinoma. Moreover, stratification based on combined SIGLEC-15 and PD-L1 CPS expression revealed that patients co-expressing high levels of both markers experienced the poorest survival outcomes. These findings suggest that the dual assessment of SIGLEC-15 and PD-L1 may enhance prognostic accuracy and support immunotherapeutic decision-making in gastric cancer.
Cutaneous metastases from internal organ cancers are diagnosed in approximately 0.2% of skin biopsies. This diagnosis can be the first sign of a previously undiagnosed malignancy with an internal organ origin. We conducted a retrospective study that included all cases of cutaneous metastases diagnosed in our hospital. A total of 25 patients were identified (14 females and 11 males). The average age of the patients included was 62.3. The most common primary cancer site was the lung for male patients, while for female patients it was the breast. In seven of our cases, cutaneous metastases were the first sign of an internal organ cancer. Common sites for cutaneous metastases in our study involved the anterior thoracic wall, the abdomen, and the scalp. Our study aims to highlight the importance of recognizing the histopathology of metastatic tumors and differentiating them from primary skin neoplasms. Immunohistochemistry is a mandatory tool for differential diagnosis in all cases, especially for patients who do not have a history of neoplasia.
Cutaneous melanoma is one of the most aggressive skin cancers. Over the years, multiple studies have focused on identifying novel treatment strategies, with increasing attention directed toward immune-modulating mechanisms within the tumor microenvironment. Among these, ATP-binding cassette transporters and stem-associated pathways have been shown to influence drug response and immune escape. ABCB5 is a gene with multiple isoforms that significantly influences the immune response. In melanoma, the ABCB5α isoform is predominantly expressed, particularly in tumor stem-like cells where it promotes chemoresistance through active drug efflux. ABCB5 has also been linked to the regulation of PI3K/Akt, BCL-2, and miR-145-associated pathways. Moreover, ABCB5-positive cells contribute to the formation of an immunosuppressive microenvironment by secreting cytokines (IL-6, IL-8, TGF-β) and expressing immune checkpoint ligands, such as PD-L1, thereby favoring tumor progression and a poor prognosis. This review integrates current data on the molecular and microenvironmental mechanisms underlying melanoma progression and therapy resistance, and positions ABCB5 within the broader landscape of melanoma resistance mechanisms, emphasizing both its potential and its current limitations as a biomarker and therapeutic target.
Secondary lymphoma of the prostate is described as the involvement of the prostate gland by lymphomatous spread from a primary site. This condition is exceedingly rare and often presents diagnostic and therapeutic challenges. The symptoms often mimic those of benign prostatic hyperplasia or prostate cancer, including LUTS (lower urinary tract symptoms) and even complete urinary retention. Here, we present a rare case of a 62-year-old male patient undergoing chemotherapy for stage IV mantle cell stomach lymphoma and subsequently secondary prostatic involvement. The patient presented with complete urinary retention, accompanied by biochemical (PSA = 11.7 ng/mL) and imaging (Magnetic Resonance Imaging-PIRADS V lesion) suspicion for prostate cancer. Histopathologic analysis of the MRI-targeted prostate fusion biopsy revealed secondary prostatic lymphoma. The chosen treatment was transurethral resection of the prostate (TUR-P) for relief of symptoms, which significantly improved urinary function (postoperative IPSS = 5 and Qmax = 17 mL/s). This case underscores the importance of considering prostatic lymphoma in the differential diagnosis of bladder outlet obstruction, especially in patients with a known lymphoma history. This report also provides a focused review of the literature on secondary prostatic lymphoma, highlighting the diagnostic challenges, treatment options, and clinical outcomes.
Cutaneous melanoma is one of the most aggressive skin cancers known. Over the years, multiple studies have focused on researching novel treatment options. For this purpose, numerous areas have been analyzed, and the focus has shifted toward the mechanisms by which immune-modulating molecules act within the microenviron-ment. Among these, ATP-binding cassette transporters and stem-associated pathways have been shown to influence drug response and immune escape. ABCB5 is a gene with multiple isoforms that significantly influences the immune response. In melano-ma, the ABCB5α isoform is predominantly expressed, primarily in tumor stem-like cells. Thus, it can alter the effects of medications by promoting chemoresistance via ac-tive drug efflux. The gene also regulates pathways PI3K/Akt, BCL-2, and miR-145, leading to overexpression. ABCB5 positive cells create an immunosuppressive micro-environment via cytokines (IL-8, IL-6, TGF-β) and death ligands (PD-L1), favoring tumor progression, thus correlating with poor prognosis. This review integrates cur-rent data on the molecular and microenvironmental mechanisms, underlying mela-noma progression and therapy resistance, highlighting ABCB5 as one of the several emerging biomarkers with potential prognostic and therapeutic relevance.
Introduction: Cutaneous adnexal tumours are a heterogeneous group of tumours arising from the adnexal structures of the skin. These include follicular, eccrine, apocrine, and sebaceous lineages. These entities display a wide morphological spectrum with overlapping histopathological features, posing significant diagnostic challenges. This study aims to provide a detailed analysis of these neoplasms. Materials and Methods: We conducted a retrospective observational study including patients with primary cutaneous adnexal tumours diagnosed in excisional specimens at our centre between 2018 and 2025. Results: A total of 82 primary cutaneous adnexal tumours were analysed in patients aged 24–90 years. A female predominance was observed (62.19%), with a mean age of 56 years among female patients and 60 years among male patients. The head and neck region was the most frequently affected site (70.73%), followed by the upper limb, thorax, and lower limb. Sweat gland tumours markedly outnumbered follicular tumours (79.27% vs. 20.73%), with hidrocystomas and spiradenomas representing the most common benign lesions. Most tumours were benign (91.46%), while atypical spiradenoma (3.66%) and malignant tumours such as eccrine porocarcinoma, trichilemmal carcinoma, and basal cell carcinoma arising in association with trichoblastoma (4.88%) were rare but clinically significant findings. Surgical specimen volumes varied significantly by anatomical site, with scalp and limb lesions reaching the largest dimensions. Margin status differed according to biological behaviour, with malignant tumours showing greater proportion of close or infiltrated margins, while margins were non-assessable in all three atypical cases. Immunohistochemical evaluation supported diagnostic confirmation in atypical and malignant cases. Conclusions: Our findings highlight the broad clinical and morphological spectrum of cutaneous adnexal tumours and contribute data from an Eastern European cohort. This study adds regional data to the limited literature on the clinicopathological distribution of cutaneous adnexal tumours and emphasises rare, atypical, and malignant diagnostic scenarios.